Articles / Author
Amir Saberi
Founder & CEO, Ambryon
Amir Saberi is a stem cell biologist and bioengineer building scalable manufacturing platforms for cell and gene therapies. Trained at the University of Illinois and Johns Hopkins School of Medicine, his work spans genome engineering, iPSC biology, and translational R&D across biotech startups. In 2024, he founded Ambryon, a biological design consulting and manufacturing development firm focused on accelerating the clinical translation of emerging cell and gene therapies.
· Industry insights · Amir Saberi
Rare Disease Gene Therapy Economics: When Small Populations Make Business Sense
Economic analysis of rare disease gene therapy development: from clinical trial advantages and pricing dynamics to manufacturing costs and business viability.
· Technology guides · Amir Saberi
Compact CRISPR Nucleases and the Future of In Vivo Gene Editing
How nuclease size dictates in vivo editing success. From SaCas9 to Cas12f and NanoCas, the evolution of AAV-compatible CRISPR systems for gene therapy.
· Design frameworks · Amir Saberi
Designing AAV That Translates: Receptor Biology, Liver De-Targeting, and Route Strategy
Master the 3 pillars of modern AAV design: receptor biology, liver de-targeting, and route strategy. A practical framework for low-dose therapeutic success.
· Technology guides · Amir Saberi
Making Base Editors Smaller for Gene Therapy
Learn how to shrink base editors for AAV gene therapy. Smaller Cas proteins, deaminase edits, and split designs. Insights for precision editing in clinical appl




